Diasorin
Develops immunodiagnostic and molecular diagnostic kits and systems for healthcare and research.
DIA | XMIL
Overview
Corporate Details
- ISIN(s):
- IT0003492391 (+2 more)
- LEI:
- 8156002878BDF0EE4348
- Country:
- Italy
- Address:
- VIA CRESCENTINO, SNC, 13040 SALUGGIA
- Website:
- https://diasoringroup.com/en
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Diasorin is a global leader in the in vitro diagnostics (IVD) market, specializing in the development, manufacturing, and commercialization of reagent kits and automated systems. The company's core focus is on two primary segments: immunodiagnostics and molecular diagnostics. In immunodiagnostics, Diasorin provides advanced solutions, including its LIAISON® family of analyzers, which detect antibodies and antigens to aid in the diagnosis of diseases. Its molecular diagnostics division offers flexible tools that use targeted and multiplex technologies to identify pathogens in biological specimens, providing healthcare providers with critical, actionable information. The company also operates in the Licensed Technology sector, offering platforms for biomedical research, clinical diagnostics, and drug discovery to help scientists find rapid and reliable answers to complex biological questions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-05 09:48 |
Communication on total amount of voting rights
|
English | 217.3 KB | ||
| 2025-12-05 09:45 |
Comunicazione dell'ammontare complessivo dei diritti di voto
|
Italian | 215.4 KB | ||
| 2025-11-10 10:42 |
Comunicato Internal Dealing
|
Italian | 94.9 KB | ||
| 2025-11-05 17:44 |
Diasorin 9M 2025 Results Presentation
|
Italian | 2.2 MB | ||
| 2025-11-05 17:43 |
Diasorin’s Board of Directors approves results for the first 9 months of 2025. …
|
English | 362.4 KB | ||
| 2025-11-05 17:42 |
Il Consiglio di Amministrazione di Diasorin approva i risultati dei primi 9 mes…
|
Italian | 478.5 KB | ||
| 2025-10-07 10:03 |
Communication on total amount of voting rights
|
English | 229.7 KB | ||
| 2025-10-07 10:01 |
Comunicazione dell'ammontare complessivo dei diritti di voto
|
Italian | 210.3 KB | ||
| 2025-09-05 10:34 |
Communication on total amount of voting rights
|
English | 206.3 KB | ||
| 2025-09-05 10:32 |
Comunicazione dell'ammontare complessivo dei diritti di voto
|
Italian | 209.6 KB | ||
| 2025-08-07 11:29 |
Interim Financial Report as at June 30, 2025
|
English | 3.0 MB | ||
| 2025-08-04 16:51 |
Pubblicazione della Relazione finanziaria semestrale al 30 giugno 2025
|
Italian | 184.4 KB | ||
| 2025-08-04 15:32 |
Relazione Finanziaria Semestrale del Gruppo Diasorin al 30 giugno 2025
|
Italian | 3.4 MB | ||
| 2025-07-31 16:24 |
Diasorin H1 2025 Results Presentation
|
English | 1.4 MB | ||
| 2025-07-31 16:22 |
Revenue Growth and Margin Expansion in H1 2025. FY 2025 Guidance Confirmed
|
English | 342.3 KB |
Automate Your Workflow. Get a real-time feed of all Diasorin filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Diasorin
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Diasorin via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
